Pharmaceuticals
60 recent notes from companies in this sector. 20 companies tracked.
Granules India locks in sole FTF for generic LUMRYZ
The company's second sole first-to-file ANDA positions it for 180-day exclusivity in the U.S. narcolepsy market and strengthens its complex generics franchise.
Supriya Lifescience GM in judicial custody for NDPS export lapse
Company says no material impact on operations, citing isolated procedural lapse in a single export transaction.
Fermenta wins FSSAI nod for plant-based Vitamin D3
VITADEE Green gets regulatory clearance, opening India's vegetarian supplement market for a micro-cap with trailing revenue decline.
Bliss GVS picks new CEO as Anupam Rasayan era begins
Rahul Adakmol, ex-Dr. Reddy's executive, takes charge from July 2026. Current CEO Narsimha Kamath stays on as MD during transition.
Rubicon's Pithampur plant gets two minor FDA observations in first audit
The US FDA inspected the acquired site for the first time, issuing a Form 483 with two procedural observations unrelated to data integrity. Management reaffirms commercial ramp-up on track for Q1 CY2027.
Zydus and Apollo bring Guardant's multi-cancer blood test to India
The Shield test, already exclusive to Zydus, will now screen across Apollo's network. No financial terms disclosed.
Ajanta Pharma promoters pledge 13.5% equity to back ₹3,873 cr outside debt
Three promoter entities have encumbered all their holdings, securing debentures of two unrelated private companies. The full scale and purpose are revealed for the first time, raising invocation risk for shareholders.
Ajanta Pharma promoter pledges 10.06 lakh shares; encumbered stake at 10.83%
The incremental 0.80% of equity is below the materiality threshold, but it adds to a flurry of promoter actions in June. Loan terms undisclosed.
Asston Pharma to raise ₹27.7 cr via preferential issue, 28% dilution
The nano-cap pharma company is selling a 28% stake to non-promoter investors, including a 12% block to Vijay Rathee, in a deal that could reshape control and pricing.
Veerhealth Care dilutes 31% of equity with ₹20.25 cr warrant issue
Promoter entities take 55% of 1 crore fully convertible warrants; capital raise equals nearly a third of market cap
OneSource gets single FDA observation, PAT collapse looms larger
A routine US FDA inspection at its Bengaluru sterile facility ended with one observation. A benign outcome, but with profit after tax down 95.3%, the agency finding is not the main worry.
Deccan Healthcare taps internal candidate as CFO after sudden exit
Tushar Mandal, an eight-year veteran, takes over from Parth Palera who resigned last week. A governance fill-up, not a surprise.
Glenmark starts Phase 3 trial for ovarian cancer ADC in India
India is first to enroll in a multi-country study for Trastuzumab rezetecan. The drug, in-licensed from Hengrui, excludes major markets like the US and Europe, limiting financial upside.
Gujarat Themis promoter stake is now tied to third-party debt
CTL Trusteeship discloses indirect encumbrance of the entire 47.02% promoter holding to secure debentures of OSS Software Solutions Labs, a previously undisclosed development that exposes the controlling block to enforcement risk.
Themis Medicare promoter pledges 27.49% stake for outside entity's debenture
Vividhmargi Trust created a pledge over 2,53,17,620 shares (27.49% of Themis Medicare) in favour of CTL Trusteeship for a debenture issuance by OSS Software Solutions Labs.
Lupin's Somerset plant gets FDA's cleanest inspection verdict
US FDA issues EIR with VAI classification for Lupin's New Jersey facility after April inspection, confirming no objectionable conditions. Analyst says outcome is routine for the ₹1 lakh cr pharma major.
Alkem wins ₹660 cr tax dispute, says no material impact
CIT Appeals deletes disallowances under Section 80-IE for five years, but the pharma major calls the sum immaterial relative to its ₹64,864 cr market cap.
Lupin wins wider European label for rare-disease drug NaMuscla
EMA approves NaMuscla for pediatric use and adds lower-dose capsules. The drug treats myotonia in a disease affecting only one in every 100,000 people, a niche win for a ₹1-lakh-cr pharma.
Sai Parenterals locks in ₹1,300-cr Australian OTC deal, 3.4x annual revenue
The 7.5-year exclusive supply contract validates the Noumed acquisition and provides transformational scale for the ₹2,586-cr market-cap company.
Glenmark gets six FDA observations at Goa plant; supply unaffected
The USFDA inspection ended June 30 with six procedural observations; Glenmark says no impact on commercial products and will respond timely. Observations avoid data integrity and repeat findings.
Jubilant Pharmova's ₹53.37 cr tax setback
Income tax rectification order disallows brought-forward losses at subsidiary Jubilant Biosys, but the company says it will appeal and sees no material impact.
Morepen elevates Sanjay Suri to joint MD from July 2026
The internal re-designation formalises existing roles alongside brother Sushil Suri. No change in strategy or control.
Corona Remedies fires up EU-GMP hormone plant, adds 20% capacity
The new Ahmedabad facility, spanning 1 lakh sq ft, targets regulated export markets with 194M tablets/capsules annual capacity, turning a regulatory milestone into revenue generation.
Shilpa Medicare partners with Orion for Nivolumab biosimilar in Europe
Shilpa Biologicals will develop and supply the biosimilar; Orion handles EU regulatory and marketing. Originator Nivolumab had $4.1B in European sales in 2025.
Medico Remedies' credit line more than doubles to ₹42 cr, rating reaffirmed
CRISIL reaffirms BBB-/Stable while enhancing rated facilities by ₹23 cr, a key capacity move for a nano-cap exporter with 37% revenue growth.
Jagsonpal Pharma buys hospital distributor for ₹20.8 cr
The cash deal adds ₹53 cr in revenue and a hospital channel, funded entirely from internal accruals.
Beryl Drugs promoter crosses 10% with small open-market buy
Sudhir Sethi picked up 6,950 shares, lifting his stake from 9.915% to 10.055%. The ₹12 cr nano-cap sees a modest signal of promoter confidence.
Astal Labs authorises ₹300 cr fundraise, acquisition hunt near 80% of market cap
The nano-cap is pursuing a ₹300 cr raise and a hunt for USFDA-compliant pharma plants. Both moves would transform the business if executed.
Mumbai investor Niraj Shah buys 6.44% stake in zero-revenue Bacil Pharma
Shah picks up 925,000 shares over three days as other holders reduce. The nano-cap reported zero operating revenue for FY26 but may be eyeing a fundraise.
Bacil Pharma loses another large holder as Shah sells 2.75% stake
Manubhai Amrutlal Shah's latest sale brings his June total to over 8%, following last week's 7.10% exit by another substantial shareholder, as the nano-cap sits on zero revenue and a market cap of ₹60 crore.
Gujarat Inject loses Chairman, CFO & Whole-Time Director in single death
Deepak Diwan Bachwani died just weeks after taking charge following the MD's exit. The nano-cap's solar pivot now faces immediate execution risk.
Jubilant Pharmova's ₹107.89 cr tax demand cut to ₹42.41 cr
Rectification order restores ₹65.48 cr in tax losses for subsidiary Jubilant Generics, but the company continues to appeal the remaining amount on merits.
Bacil Pharma loses another big holder — Patel cuts stake by 7.10%
Nikita Hiren Patel sold nearly a third of her remaining stake, dropping from 17.17% to 10.07%. The ₹60-cr nano-cap has zero operating revenue.
Shilpa Medicare commissions ADC facility, targets global CDMO play
The Dharwad plant is fully operational and entering GMP qualification; the company aims to become a cost-competitive CDMO partner for oncology drug makers.
Biocon scores MYR 225 mn insulin supply deal in Malaysia
Duopharma Biotech's tender wins from Malaysia's MOH secure Biocon a three-drug supply agreement, but the annualized revenue is modest relative to its size.
Goldline promoter lifts stake to 29.27% with open-market buy
Swapan Khandelwal bought 60,000 shares (0.62% of equity) on 22 June. No pledging. For a nano-cap with a market cap of just ₹42 cr, it's a rare vote of confidence.
Bacil Pharma board to mull fundraising options on June 26
Nano-cap with zero operating revenue calls a board meeting to consider preferential issue, rights issue, or other modes. No concrete details yet.
Eris targets 18-20% international growth in FY27 despite EU site snag
A corporate presentation reveals fresh FY27 guidance for the international business and confirms an EU inspection that delayed commercialisation of its EU-CDMO pipeline but left existing operations intact.
Sun Pharma buys Innovcare Lifesciences for ₹271 cr
A bolt-on acquisition that adds a portfolio of drugs and nutraceuticals, but at just 0.06% of market cap, it won't move the needle for India's largest drugmaker.
Astonea Labs profit slides to ₹451.52 lakhs; ₹9.39 cr fire loss uninsured
Audited FY26 results show net profit of ₹451.52 lakhs, down from ₹535.06 lakhs. A post-year factory fire caused ₹9.39 crores in damages; insurance claim not yet filed.
Panjon's FY26 results get clean audit, but no surprises
Audited numbers confirm 56% revenue jump to ₹47.62 cr, but net profit remains thin at ₹0.60 cr. All key figures were already disclosed.
Brooks Labs nets ₹106 cr from stake sale, 53% of its market cap
Partial monetisation of Brooks Steriscience stake fetches ₹106 crore in cash, a huge inflow for the nano-cap drug maker that nearly doubles its cash position.
Shelter Pharma's Q1 exports hit ₹5 cr, nearly matching FY26 full year
Q1 FY27 exports have already surpassed ₹5 crores, close to the ₹6 crores earned in all of FY26. The nano-cap also targets ₹200 crore revenue by FY30 with aggressive expansion.
Sandu Pharma faces void after MD Umesh Sandu's sudden death
The ayurvedic drugmaker's promoter and managing director has died, leaving a leadership gap at a nano-cap firm with ₹41 cr market cap and no successor named yet.
Ajanta Pharma promoter trust releases 23.26 lakh pledged shares
Ravi Agrawal Trust cuts encumbered stake to 2.75% from 4.61%, citing excess pledge. The move trims total promoter group encumbrance to about 15% and follows a ₹1,046 cr share sale earlier this month.
Alembic eyes $259M cancer market with tentative US nod for Binimetinib
Sole first applicant with Paragraph IV, Alembic qualifies for 180-day generic exclusivity on a melanoma and NSCLC drug. This is its largest single-product opportunity this year.
Aurobindo gets FTC nod for Lannett, moves closing to June
The US regulator clears a key hurdle for the generics deal announced last July. Aurobindo now expects to close before end of June, ahead of initial guidance.
Dugar family launches open offer for 26% of Colinz at ₹54/share
A mandatory open offer follows a share purchase agreement for a 34.56% stake, handing control of the nano-cap pharma company to the Dugar family for a combined ₹7.89 crore, over half its market cap.
P&G Health's FY26 sales up 16%, profit up 30%; innovation and distribution gain
Concall confirmed strong revenue and profit growth. New products beat expectations, distribution added 30k extra-urban pharmacies. No FY27 guidance but management sees sustained momentum.
Bacil Pharma proposes R&D arm, but numbers are missing
The nano-cap with zero revenue wants a wholly-owned R&D subsidiary. No investment amount or timeline disclosed, just an intent.
Lupin launches Azilsartan generic in US with 180-day exclusivity
First-to-file Azilsartan Medoxomil tablets hit the US market, but the $53.5M reference product adds less than 0.3% to Lupin's annual revenue.
Kilitch Drugs starts nutraceutical block, no revenue numbers
New manufacturing block begins at greenfield facility but capacity and investment undisclosed.
Suven's Ropanicant clears Phase 2b, cuts depression scores 3.6 points vs placebo
The 214-patient trial met its primary endpoint with statistical significance. Suven now pushes to global Phase 3 registrational studies.
Suven's experimental cognitive drug clears Phase 1 safety hurdle
SUVN-I6107, Suven's fifth internally discovered neuroscience NCE, showed no serious adverse events in 64 healthy volunteers and is moving into Phase 2.
Sudarshan Pharma board to weigh fund raise on June 18
The micro-cap drugmaker will discuss equity, convertible, or debt options, but the size, structure, and pricing remain undisclosed — leaving dilution or debt risk unclear.
Lactose to forfeit 15 lakh warrants after SG General fails to pay
The board will consider stripping SG General Dealers LLP of its convertible warrants for non-payment. The move removes a potential dilution but also signals a counterparty default.
Ajanta Pharma promoter pledges additional 0.89% stake to RBL Bank
The latest pledge, along with a 2.2% pledge two days ago, brings total encumbered promoter holdings to 10.05%. The moves follow a ₹1,046 cr stake sale on June 9.
Trident Lifeline gets board nod for main board migration
The nano-cap pharma company plans to shift from BSE SME to main boards of BSE and NSE. New independent directors bring financial and pharma expertise.
Kabra Drugs lands ₹200 cr LOI from Chhattisgarh for pharma plant
The nano-cap pharma firm received a letter of intent from the state government for a facility at Nava Raipur Pharma Park, an investment worth over 3.5 times its market cap.
Dr. Reddy's launches first generic Bosulif analogue with 180-day US exclusivity
The generic Bosutinib 400mg, equivalent to Pfizer's $254M brand, hits the US market. A win for Dr. Reddy's first-to-file strategy, but not a needle-mover for a ₹1,06,454 cr behemoth.